Abstract

Artificial intelligence (AI) has emerged as a disruptive force in the field of pharmacology and clinical trials, bringing about a paradigm shift in how drugs are developed, tested, and administered. This review article provides an overview of the current state and future potential of harnessing AI in pharmacology and clinical trials. The article begins by exploring the applications of AI in drug discovery and development. It discusses how machine learning algorithms can analyze vast amounts of data, including genomic information, chemical structures, and clinical data, to accelerate the identification and optimization of potential drug candidates. The integration of AI-based approaches, such as virtual screening and de novo drug design, offers a more efficient and cost-effective pathway for drug discovery.